Medical Patent Law Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Bioenvision

Reports describe the most recent news from Bioenvision

This trend article is an immediate alert from NewsRx to identify the most recent news developments at Bioenvision.

Report 1: Bioenvision, Inc., (BIVN) has completed the substantive work and analysis involved with finalizing the Marketing Authorization Application (MAA) to expand the Evoltra (clofarabine) label and is now involved with the administrative aspects of formally submitting the filing to the European Medicines Agency (EMeA) for the use of Evoltra in adult AML patients over 65 years and who are considered unsuitable for intensive therapy.

The formal submission of the...

• View Other Issues of Medical Patent Law Weekly
  
• View Other NewsRx Publications